Intragenic variability of human cytomegalovirus glycoprotein B in clinical strains

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1162-1169

  Meyer König, Ursula ^a   Haberland, Michael ^a   Von Laer, Dorothee ^a,b   Haller, Otto ^a   Hufert, Frank T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL SEQUENCE; ARTICLE; CYTOMEGALOVIRUS; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; VIRUS VIRULENCE;

EID: 0031923758     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515262     Document Type: Article

References (14)

1. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 1993;197:143-58.
2. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-85.
3. Utz U, Britt W, Vugler L, Mach M. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 1989;63: 1995-2001.
4. Meyer H, Sundqvist VA, Pereira L, Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 1992;73:2375-83.
5. Basgoz N, Qadri I, Navarro D, Sears A, Lennette E, Youngblom JP. The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains. J Gen Virol 1992;73:983-88.
6. Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988;168: 919-31.
7. Charpentier B, Michelson S, Martin B. Definition of human cytomegalovirus-specific target antigens recognized by cytotoxic T cells generated in vitro by using an autologous lymphocyte system. J Immunol 1986; 137:330-6.
8. Liu YN, Curtsinger J, Donahue PR, et al. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93. J Gen Virol 1993;74: 2207-14.
9. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991;146:2795-804.
10. Chou SW, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 1991;163:1229-34.
11. Chou S. Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus. Virology 1992;188:388-90.
12. Lehner R, Stamminger T, Mach M. Comparative sequence analysis of human cytomegalovirus strains. J Clin Microbiol 1991;29:2494-502.
13. Fries BC, Chou S, Boeckh M, Torok Storb B. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis 1994;169:769-74.
14. Rasmussen L, Hong C, Sherman D, Zipeto D, Chou S, Merigan T. Distribution of CMV glycoprotein UL55 (gB) and UL 75 (gH) sequence variant groups in patients infected with HIV [abstract 28]. In: Program and abstracts of the Vth International Cytomegalovirus Conference (Stockholm). Stockholm: Norstedts Tryckeri, 1995:74.